Dianthus Therapeutics Shares Rise 320% Year-to-Date Despite Major Stake Reduction by Octagon Capital Advisors
Shares of Dianthus Therapeutics (NASDAQ:DNTH) have surged over 320% in the past year, outperforming the S&P 500. However, major investor Octagon Capital Advisors reduced its stake by $27.22 million during Q1 2026 while still maintaining a significant position representing nearly 18% of its assets under management.
Tickers: $DNTH
Topics: biotech SEC filing stock ownership